ER-positive
Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials
Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)
Actionable Insights Powered by AI
Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)